background
multipl
sclerosi
ms
afflict
million
individu
worldwid
number
increas
time
within
past
year
great
number
diseasemodifi
treatment
emerg
howev
efficaci
treatment
cure
ms
await
discoveri
thymosin
solubl
hormonelik
peptid
produc
thymu
gland
mediat
immun
nonimmun
physiolog
process
gain
interest
recent
year
therapeut
inflammatori
autoimmun
diseas
method
pubm
search
time
constraint
articl
use
combin
keyword
thymosin
thymu
factor
multipl
sclerosi
mesh
term
languag
restrict
result
review
stateoftheart
effect
thymosin
ms
experiment
model
particular
describ
known
field
role
potenti
antiinflammatori
well
neuroprotect
remyelin
molecul
mechan
action
conclus
base
data
act
antiinflammatori
molecul
induc
myelin
repair
neuron
protect
respect
possibl
therapeut
applic
ms
alon
combin
approv
drug
may
envisag
approach
reason
light
current
clinic
usag
data
demonstr
safeti
toler
efficaci
clinic
practic
ascherio
munger
b
enigmat
immunemedi
diseas
central
nervou
system
cn
display
progress
neurodegener
due
immun
attack
directli
myelin
constitu
caus
myelin
destruct
lassmann
et
al
genet
suscept
individu
treatment
develop
past
year
extrem
activ
great
number
potenti
new
therapi
emerg
patient
ms
ms
therapeut
approach
focus
past
three
decad
strategi
reduc
inflamm
immun
activ
act
immunomodul
migrat
specif
inflammatori
cell
subset
agent
directli
mediat
neuroprotect
neurorestor
diseasemodifi
therapi
shown
benefici
effect
patient
relapsingremit
ms
rrm
major
drug
howev
littl
benefit
progress
ms
axon
degener
follow
demyelin
outweigh
inflamm
obviou
reason
discrep
therapeut
efficaci
approv
drug
spark
great
interest
develop
new
remyelin
therapi
aim
provid
neuroprotect
function
recoveri
monotherapeut
strategi
suppress
immun
cell
attack
cn
insuffici
prevent
amelior
perman
accumul
ms
deficit
kremer
et
al
addit
therapi
ms
urgent
requir
enhanc
remyelin
reduc
axon
damag
improv
function
recoveri
demyelin
loss
myelin
sheath
axon
result
damag
death
myelin
produc
oligodendrocyt
ol
remyelin
requir
oligodendrocyt
progenitor
cell
opc
differenti
matur
myelin
ol
matur
ol
adult
mammalian
cn
post
mitot
thu
unabl
prolifer
respons
injuri
form
new
myelin
sheath
mctigu
tripathi
keirstead
blakemor
failur
newli
gener
ol
remyelin
axon
preserv
axon
integr
imped
function
recoveri
ms
kremer
et
al
cell
therapi
includ
stem
cell
transplant
potenti
cn
repair
may
abl
provid
protect
inflammatori
damag
caus
injuri
rice
et
al
glial
cell
commun
network
includ
astrocyt
microglia
also
play
import
role
deremyelin
domingu
et
al
thu
import
investig
treatment
strategi
ms
would
includ
immunomodul
pair
neuroprotect
neurorestor
mani
new
molecul
previous
approv
drug
develop
highthroughput
screen
appear
posit
impact
remyelin
neuroprotect
therapeut
pipelin
envisag
use
alon
part
combin
therapi
includ
immunomodulatori
drug
treatment
ms
harlow
et
al
although
benefici
effect
drug
cn
cell
encourag
care
studi
offtarget
effect
need
undertaken
given
mani
drug
origin
util
noncn
target
thymic
hormonelik
molecul
thymosin
evid
emerg
regul
thymic
peptid
hormon
thymosin
antiinflammatori
potenti
inflammatori
well
autoimmun
diseas
lunin
novoselova
context
earli
studi
conduct
use
thymosin
fraction
v
treat
old
mice
endoh
tabira
guinea
pig
woyciechowska
et
al
subject
model
ms
experiment
autoimmun
encephalomyel
eae
treatment
show
suppress
effect
incid
sever
diseas
first
studi
endoh
tabira
howev
eae
induc
age
mice
suscept
diseas
may
significantli
reduc
inde
set
also
treatment
anoth
thymic
protein
serum
thymic
factor
show
effect
differ
observ
group
describ
intens
suppress
eae
symptom
nagai
et
al
moreov
thymosin
fraction
v
partial
purifi
mixtur
major
least
polypeptid
thymu
gland
extrem
vari
import
biolog
properti
may
act
individu
sequenti
concert
influenc
develop
cell
subset
could
also
mediat
inhibitori
effect
observ
experi
conduct
singl
mixtur
purifi
thymosin
hoch
volk
goldstein
badamchian
inde
therapeut
benefit
observ
damag
cn
neurolog
disord
includ
ms
synthet
form
thymosin
singl
peptid
purifi
thymosin
fraction
v
abl
pass
blood
brain
barrier
mora
et
al
exogen
administ
use
anim
model
neurolog
injuri
studi
demonstr
target
multipl
neural
cell
includ
neuron
oligodendrocyt
microglia
also
provid
neuroprotect
immunosuppress
neurorestor
includ
remyelin
synaptogenesi
axon
growth
zhang
et
al
b
chopp
zhang
santra
et
al
santra
et
al
wang
et
al
wang
et
al
cheng
et
al
furthermor
studi
show
purifi
prothymosin
precursor
thymosin
abl
regul
defect
phenotyp
monocyt
ms
impact
cell
activ
reclo
et
al
baxevani
et
al
recent
antiinflammatori
potenti
differenti
regulatori
subset
lymphocyt
also
studi
ms
giacomini
et
al
review
describ
detail
known
role
promot
remyelin
antiinflammatori
respons
ms
potenti
mechan
action
literatur
search
carri
pubmedmedlin
databas
author
deem
import
miss
potenti
relev
studi
therefor
comprehens
search
strategi
set
limit
fix
languag
date
public
base
review
topic
search
strategi
includ
control
vocabulari
freetext
word
synonym
mesh
term
relat
thymosin
thymosin
thymu
factor
thymu
peptid
thymic
peptid
thymosin
fraction
thymosin
beta
thymosin
alpha
prothymosin
combin
main
search
filter
multipl
sclerosi
final
refer
list
gener
consid
titl
relev
review
topic
base
onlin
search
updat
june
well
citat
bibliographi
author
suggest
thymu
gland
produc
solubl
hormonelik
peptid
mediat
immun
nonimmun
physiolog
process
thymosin
origin
prepar
crude
extract
mous
rat
thymu
gland
next
decad
first
biolog
activ
thymic
extract
purifi
call
thymosin
fraction
v
fraction
led
isol
seri
immunoact
polypeptid
thu
name
thymosin
goldstein
howev
molecul
genet
unrel
distribut
wide
throughout
tissu
play
import
yet
differ
role
cell
activ
peptid
typic
short
highli
charg
aromat
amino
acid
therefor
intrins
unstructur
protein
natur
condit
hoch
volk
start
fraction
v
sever
main
peptid
polypeptid
differ
isol
test
biolog
activ
tabl
thymosin
divid
main
group
base
isoelectr
focus
pattern
thymosin
fraction
v
ph
ph
ph
numer
subscript
simpli
denot
chronolog
order
isol
first
two
peptid
isol
fraction
v
polypeptid
gener
peptid
isol
region
thymosin
fraction
v
appear
thymusspecif
product
predomin
band
region
polypeptid
show
biolog
activ
though
promin
compon
thymosin
fraction
v
later
identifi
residu
fragment
ubiquitin
lack
two
glycin
residu
cterminu
hoch
volk
next
thymosin
isol
sequenc
term
success
isol
hoch
volk
mani
ortholog
human
thymosin
gene
share
chromosom
locat
andor
sequenc
similar
character
differ
speci
summari
main
thymosin
gene
characterist
tissu
distribut
human
mous
see
tabl
sever
attempt
made
tri
character
cellular
receptor
involv
thymosin
recognit
howev
far
none
identifi
rinaldi
garaci
et
al
brelinska
warchol
todat
main
member
thymosin
famili
consid
precursor
well
mosoian
highli
acid
protein
wide
distribut
differ
cell
type
express
intracellular
extracellular
level
human
famili
gene
consid
pseudogen
encod
mosoian
major
intracellular
function
link
chromatin
remodel
cell
prolifer
differenti
apoptosi
also
found
overexpress
differ
cancer
type
mosoian
extracellular
share
mani
featur
interleukin
il
thu
repres
import
endogen
stimul
innat
immun
system
relat
antivir
anticanc
antifung
antiischem
activ
well
adjuv
vaccin
mosoian
note
signal
via
tolllik
receptor
tlr
requir
potent
antihuman
immunodefici
viru
hiv
activ
macrophag
via
type
ifn
induct
mosoian
peptid
amino
acidslong
contain
nterminu
precursor
nearli
baseslong
shown
lysosom
asparaginyl
endopeptidas
socal
legumain
abl
proteolyt
process
asparagynilglycin
residu
asn
gli
gener
sarandes
et
al
sinc
discoveri
investig
mainli
perform
area
infecti
diseas
administr
studi
wide
varieti
anim
human
set
pharmacolog
effect
shown
enhanc
cellular
immun
inhibit
viral
replic
differ
virus
base
data
use
treatment
chronic
hepat
b
c
iino
et
al
et
al
cytomegaloviru
infect
bozza
et
al
invas
aspergillosi
romani
et
al
addit
postmarket
data
zadaxin
sciclon
clearli
confirm
immunomodulatori
activ
relat
therapeut
potenti
also
cancer
hepatocellular
carcinoma
lung
cancer
melanoma
infecti
diseas
sepsi
infect
bone
marrow
transplant
lung
infect
includ
chronic
obstruct
pulmonari
disord
sever
acut
respiratori
syndrom
hiv
king
tuthil
liu
et
al
matteucci
et
al
jia
et
al
improv
immun
respons
elderli
immunocompromis
patient
exampl
enhanc
respons
vaccin
tuthil
et
al
famili
compos
short
amino
acid
peptid
among
three
character
detail
howev
found
upregul
differ
malign
human
prostat
cancer
repres
potenti
biomark
bao
et
al
healthi
human
bodi
express
huff
et
al
peptid
play
numer
differ
function
among
other
affect
process
carcinogenesi
differenti
angiogenesi
influenc
metalloproteinas
activ
acceler
wound
heal
highli
conserv
acid
peptid
wide
distribut
mammalian
tissu
includ
cn
major
gactinsequest
molecul
primari
physiolog
function
regul
cell
motil
bockmarquett
et
al
chopp
zhang
kuzan
goldstein
kleinman
rat
mice
human
cattl
cytoskeleton
organ
morpholog
prolifer
motil
antiinflammatori
effect
insulin
secret
sribenja
et
al
zhang
et
al
rat
mice
human
motil
progress
metastati
nonsmal
cell
lung
cancer
banyard
et
al
develop
cn
regul
neurogenesi
tangenti
expans
tissu
growth
hemispher
fold
lever
et
al
wirsch
et
al
wirsch
et
al
initi
employ
antiinflammatori
agent
badamchian
et
al
girardi
et
al
subsequ
inhibit
prolifer
induc
differenti
apoptosi
leukem
cell
huang
et
al
recent
heal
properti
describ
skin
cornea
cardiac
repair
zhang
et
al
chopp
zhang
bockmarquett
et
al
badamchian
et
al
li
et
al
kim
et
al
goldstein
et
al
neuroprotect
wellinvestig
effect
santra
et
al
xiong
et
al
spinal
cord
injuri
traumat
brain
injuri
model
treatment
significantli
improv
locomotor
sensorimotor
function
recoveri
spatial
learn
well
increas
surviv
neuron
ol
reduc
cortic
lesion
volum
neurolog
injuri
cheng
et
al
xiong
et
al
vitro
exogen
treatment
significantli
reduc
apoptosi
neural
progenitor
cell
subject
oxygen
glucos
depriv
santra
et
al
moreov
may
also
drive
neuroprotect
eae
eae
model
wide
employ
investig
studi
ms
sinc
exhibit
signific
neurolog
function
deficit
well
obviou
patholog
chang
includ
demyelin
inflammatori
infiltr
procaccini
et
al
eng
et
al
administ
prophylact
treatment
day
proteolipid
protein
peptid
plp
immun
treatment
significantli
delay
eae
onset
evok
significantli
improv
neurolog
function
recoveri
sinc
matur
ol
myelin
support
axon
integr
function
nave
investig
found
robust
function
improv
accompani
increas
number
matur
ol
cn
eae
mice
zhang
et
al
sinc
eae
model
induc
autoimmun
respons
antiinflammatori
immunomodulatori
properti
badamchian
et
al
girardi
et
al
sosn
et
al
via
suppress
nuclear
factorkappa
b
nfkb
activ
sosn
et
al
may
protect
ol
damag
death
addit
inflammatori
cell
infiltr
peripher
circul
microglia
resid
innat
immun
cell
cn
activ
neuroinflamm
play
pivot
role
onset
patholog
chang
diseas
thu
effect
exogen
treatment
inhibit
microgli
activ
damag
may
contribut
reduc
secret
inflammatori
mediat
zhang
et
al
zhou
et
al
therebi
prevent
andor
reduc
damag
ol
eae
attenu
immun
onslaught
neuroprotect
import
aspect
studi
novel
evid
show
prophylact
treatment
may
contribut
remyelin
sinc
treatment
abl
promot
increas
new
ol
gener
opc
prolifer
differenti
zhang
et
al
investig
remyelin
effect
treatment
window
delay
permit
full
develop
demyelin
damag
cn
eae
anim
therapeut
treatment
administ
eae
symptom
onset
instead
day
plp
immun
function
outcom
reveal
treatment
approach
evok
signific
function
benefit
zhang
et
al
concurr
increas
ol
demyelin
cn
earli
stage
eae
day
onset
protein
level
myelin
basic
protein
mbp
number
ol
strongli
decreas
convers
ol
significantli
increas
treatment
suggest
newli
gener
ol
form
new
myelin
contribut
improv
function
recoveri
hypothesi
support
result
also
opc
differenti
significantli
induc
axon
rewrap
axon
damag
reduc
treatment
late
stage
eae
day
onset
opc
differenti
significantli
correl
neurolog
function
score
zhang
et
al
treatment
approach
increas
myelin
area
improv
function
outcom
late
diseas
stage
demonstr
presenc
remyelin
effect
addit
neuroprotect
antiinflammatori
effect
complement
eae
model
addit
demyelin
model
induc
cuprizon
dietwa
employ
confirm
remyelin
effect
deriv
direct
action
opc
cuprizon
model
extens
use
studi
vivo
toxicityinduc
demyelin
zhang
et
al
less
infiltr
immun
cell
compar
found
eae
procaccini
et
al
thu
experiment
model
util
directli
investig
effect
therapeut
agent
opc
differenti
remyelin
cuprizonef
mice
demyelin
treat
exhibit
signific
increas
remyelin
accompani
robust
increas
newli
gener
ol
elev
mbp
densiti
demyelin
corpu
callosum
zhang
et
al
concert
result
obtain
eae
cuprizon
model
indic
vivo
effect
opc
differenti
remyelin
independ
system
antiinflammatori
effect
data
obtain
model
neurolog
injuri
induc
demyelin
white
matter
damag
result
homo
sapien
x
ovari
endometrium
prostat
ortholog
mu
musculu
neurolog
deficit
includ
stroke
peripher
neuropathi
traumat
brain
injuri
likewis
show
benefit
opc
myelin
delay
treatment
rat
middl
cerebr
arteri
occlus
treat
demonstr
signific
overal
improv
function
outcom
morri
et
al
although
lesion
volum
reduc
treatment
increas
myelin
axon
ischem
boundari
augment
remyelin
associ
increas
opc
myelin
ol
morri
et
al
model
diabetesinduc
peripher
neuropathi
extend
treatment
diabet
mice
significantli
improv
neurolog
function
close
associ
increas
axon
regener
remyelin
peripher
nerv
wang
et
al
traumat
brain
injuri
remain
lead
caus
mortal
morbid
worldwid
effect
pharmacolog
treatment
treatment
traumat
brain
injuri
rat
amplifi
endogen
remyelin
process
includ
oligodendrogenesi
neurogenesi
axon
remodel
appear
drive
function
recoveri
xiong
et
al
vitro
experi
provid
evid
direct
effect
opc
neuron
treatment
primari
cultur
opc
differenti
opc
matur
ol
identifi
protein
level
mbp
significantli
increas
zhang
et
al
santra
et
al
thu
data
gener
vivo
vitro
studi
concert
confirm
remyelin
effect
due
combin
benefit
neuroprotect
remyelin
summar
fig
excel
candid
treatment
demyelin
diseas
also
base
data
demonstr
safeti
toler
efficaci
clinic
practic
crockford
vasilopoul
et
al
mark
kumar
vivo
vitro
studi
also
given
mechanist
insight
therapeut
effect
epiderm
growth
factor
receptor
tlr
signal
transduct
pathway
may
contribut
cn
remyelin
recoveri
function
induc
zhang
et
al
santra
et
al
hedgehog
signal
pathway
shown
involv
activ
stem
cell
treatment
may
contribut
therapeut
benefit
kim
et
al
furthermor
mind
microrna
mirna
may
directli
induc
opc
differenti
ol
zhang
et
al
liu
et
al
treatment
may
promin
stimul
express
mrna
primari
cultur
opc
thu
promot
prolifer
differenti
opc
ol
santra
et
al
may
serv
common
remyelin
therapeut
mechan
addit
increas
express
opc
remark
also
increas
express
microglia
significantli
inhibit
secret
proinflammatori
mediat
zhou
et
al
may
promot
remyelin
crockford
shown
benefici
effect
numer
immun
system
paramet
relat
innat
adapt
immun
cell
includ
macrophag
neutrophil
natur
killer
cell
dc
addit
wellcharacter
effect
differenti
matur
cell
serafino
et
al
featur
use
adjuv
immunotherapeut
agent
treat
dispar
human
diseas
includ
viral
infect
immunodefici
malign
romani
et
al
howev
demonstr
power
pleiotrop
molecul
abl
induc
antivir
proinflammatori
respons
also
promot
regulatori
milieu
depend
context
other
data
show
romani
et
al
giacomini
et
al
observ
consist
fact
neg
control
inflamm
immunopatholog
proinflammatori
infect
diseas
exert
interest
notcomplet
understood
role
homeostasi
regul
romani
et
al
context
import
underlin
anoth
interest
properti
reli
modul
regulatori
cell
treg
function
act
signal
deliv
tlr
respons
pathogen
associ
molecular
pattern
romani
et
al
montagnoli
et
al
characterist
also
recent
test
cystic
fibrosi
increas
alter
matur
cystic
fibrosi
transmembran
conduct
regul
reduc
chronic
inflamm
caus
excess
activ
innat
immun
respons
romani
et
al
inde
owe
abil
activ
tolerogen
pathway
tryptophan
catabol
via
immunoregulatori
enzym
indoleamin
puccetti
grohmann
specif
potenti
immun
toler
lung
break
viciou
circl
perpetu
chronic
lung
inflamm
respons
varieti
infecti
noxa
romani
et
al
collect
data
suggest
repres
promis
molecul
control
inflamm
immun
toler
varieti
clinic
set
includ
organ
transplant
tumor
well
autoimmun
diseas
ms
serafino
et
al
due
abil
establish
regulatori
environ
balanc
inflamm
toler
recent
hypothes
possibl
role
molecul
novel
therapeut
applic
toward
autoimmun
diseas
particular
ms
giacomini
et
al
concentr
human
serum
high
fetus
newborn
immun
system
first
develop
rapidli
drop
earli
childhood
coincid
matur
cell
bodi
remain
steadyst
level
throughout
adulthood
howev
deregul
serum
concentr
found
differ
type
cancer
infecti
diseas
recent
patient
affect
chronic
inflammatori
autoimmun
diseas
psoriat
arthriti
rheumatoid
arthriti
ra
system
lupu
erythematosu
sle
much
lower
level
serum
compar
healthi
control
pica
et
al
similarli
also
recent
found
serum
significantli
lower
rrm
patient
match
control
giacomini
et
al
hypothes
defici
endogen
level
found
patient
sera
could
relat
msassoci
alter
inflammatori
statu
alway
studi
modul
cell
respons
ms
consid
far
cellmedi
autoimmun
diseas
nonetheless
past
year
b
cell
increasingli
recogn
diseaserelev
ms
recent
evid
immunopathogen
support
ms
develop
collect
highlight
central
role
franciotta
et
al
histor
overshadow
emphasi
cell
research
tradit
b
cell
implic
ms
abil
produc
pathogen
antibodi
ab
autoab
found
present
csf
brain
tissu
ms
patient
accordingli
characterist
oligoclon
igg
band
csf
thought
quit
specif
marker
ms
walsh
et
al
numer
b
lymphocyt
also
describ
togeth
lymphocyt
dc
plasma
cell
white
matter
lesion
high
frequenc
acut
lesion
nyland
et
al
howev
new
impetu
central
role
b
cell
ms
pathogenesi
receiv
identif
mening
spm
patient
ectop
lymphoid
follicl
enrich
b
plasma
cell
whose
establish
brain
individu
could
provid
microenviron
b
cell
expans
matur
henc
local
ig
product
may
occur
serafini
et
al
nowaday
howev
import
abindepend
pathogen
role
b
cell
emerg
also
light
success
result
b
celldeplet
therapi
ms
barun
baror
particular
select
deplet
b
cell
via
monoclon
ab
b
cell
lineag
specif
surfac
marker
ie
rituximab
ocrelizumab
ofatumumab
prove
remark
effect
induct
longlast
suppress
lesion
activ
clinic
relaps
show
effect
plasma
cell
differenti
ab
product
barun
baror
importantli
b
cell
effici
present
antigen
cell
modul
local
immun
respons
secret
solubl
factor
human
differ
b
cell
subset
describ
produc
distinct
effector
cytokin
particular
b
cell
releas
mainli
antiinflammatori
memori
b
cell
larg
express
proinflammatori
factor
lymphotoxin
lt
human
b
cell
effector
cytokin
profil
stringent
contextdepend
reciproc
regul
proand
antiinflammatori
respons
ms
cytokin
network
dysregul
much
lower
product
antiinflammatori
factor
duddi
et
al
furthermor
b
cell
ms
patient
exhibit
aberr
proinflammatori
respons
increas
lt
ratio
exagger
lt
secret
may
mediat
bystand
activ
diseaserelev
proinflammatori
cell
result
new
relaps
ms
diseas
activ
baror
et
al
term
regulatori
b
cell
first
introduc
mizoguchi
bhan
indic
subset
b
cell
abil
produc
suppress
inflammatori
cellular
immun
respons
mizoguchi
bhan
sinc
famili
b
reg
expand
mani
subset
identifi
shown
aris
differ
stage
b
cell
differenti
contextdepend
manner
mauri
menon
particular
among
mani
other
two
main
b
reg
popul
deepli
character
transitionalimmatur
b
reg
aris
cell
compart
blair
et
al
plasmablastlik
b
reg
cell
differenti
memori
b
cell
matsumoto
et
al
much
evid
indic
b
cellderiv
product
strongli
downregul
ms
patient
duddi
et
al
baror
et
al
studi
character
far
b
reg
popul
ms
use
differ
ab
cocktail
lead
contrast
result
knippenberg
et
al
michel
et
al
li
et
al
habib
et
al
base
background
mind
strong
immunomodulatori
pleiotrop
activ
molecul
well
previou
data
show
dysregul
b
cell
respons
ms
patient
giacomini
et
al
rizzo
et
al
set
vitro
pbmcbase
experiment
procedur
studi
differenti
b
reg
subset
impact
context
giacomini
et
al
particular
differ
studi
purifi
b
cell
mix
cell
popul
pbmc
resembl
vivo
scenario
upon
stimul
specif
agonist
socal
imiquimod
could
account
cytokin
product
well
trigger
signal
gener
vitro
b
cell
prolifer
milieu
uniqu
either
healthi
individu
patient
use
set
studi
demonstr
strike
differ
abil
b
cell
rrm
patient
differenti
transitionalimmatur
plasmablastlik
b
reg
subset
compar
match
control
giacomini
et
al
interestingli
vitro
exposur
drastic
reduc
product
proinflammatori
cytokin
increas
express
antiinflammatori
mediat
accordingli
treatment
restor
abil
rrm
b
cell
differenti
transitionalimmatur
b
reg
regulatori
plasmablast
level
found
healthi
control
fig
furthermor
b
reg
subset
expand
treatment
display
suppress
activ
reduc
product
found
ms
patientsderiv
pbmc
cultur
giacomini
et
al
unfortun
evid
role
eae
howev
janeway
colleagu
first
observ
mice
lack
b
cell
suffer
unusu
sever
chronic
form
eae
suggest
antiinflammatori
b
cell
charg
neg
regul
inflammatori
reaction
may
deplet
wolf
et
al
therefor
envisag
treatment
impact
induct
b
regulatori
cell
subset
may
exert
protect
effect
eae
reduc
diseas
sever
concert
find
highlight
therapeut
potenti
ms
well
autoimmun
condit
show
reduc
differenti
b
reg
subset
chronic
immun
activ
ongo
research
ms
therapeut
seek
strategi
target
modul
proinflammatori
respons
antiinflammatori
scenario
antigenspecif
immun
toler
may
induc
regard
manipul
b
reg
subset
may
success
howev
sinc
approv
treatment
ms
work
reduc
immun
system
activ
block
entri
immun
cell
cn
thu
reduc
relaps
rate
sever
attack
repair
immunemedi
damag
myelin
sheath
surround
axon
drug
repurpos
develop
new
treatment
promot
myelin
repair
neuron
protect
desir
scenario
review
stateoftheart
thymosin
ms
particular
attent
neuroprotect
remyelin
action
recent
character
antiinflammatori
activ
clinic
usag
past
cancer
chronic
infect
adjuv
vaccin
formul
garaci
et
al
immun
potenti
need
may
seem
difficult
reconcil
use
autoimmun
condit
antiinflammatori
action
desir
howev
result
potenti
b
reg
differenti
ms
giacomini
et
al
togeth
wellcharacter
pleiotrop
activ
abl
shift
inflamm
toward
antiinflammatori
milieu
depend
stimuli
patholog
condit
romani
et
al
giacomini
et
al
capac
induc
treg
gener
product
romani
et
al
romani
et
al
indic
benefici
advis
function
drug
use
autoimmun
diseas
data
may
pave
way
repurpos
potenti
alon
combin
approv
drug
treatment
ms
autoimmun
condit
display
reduc
differenti
b
reg
subset
chronic
immun
activ
addit
broad
net
protect
restor
effect
neurolog
degener
injuri
cn
recent
studi
investig
remark
capac
promot
opc
prolifer
also
opc
differenti
remyelin
demonstr
signific
improv
function
behavior
outcom
anim
model
ms
abil
target
mani
divers
process
via
multipl
molecular
pathway
drive
oligodendrogenesi
axon
remodel
may
also
mediat
mirna
particularli
santra
et
al
thu
substanti
potenti
clinic
translat
multipletarget
therapi
mseae
neurolog
demyelin
diseas
remyelin
effect
supplement
antiinflammatori
neuroprotect
role
previous
found
studi
involv
prophylact
treatment
zhang
et
al
sinc
low
level
endogen
present
sera
patient
affect
chronic
inflammatori
autoimmun
diseas
psoriat
arthriti
ra
sle
pica
et
al
well
rrm
patient
giacomini
et
al
interest
approach
might
also
quantifi
level
serum
categori
patient
investig
whether
deregul
thymic
peptid
may
relat
msassoci
autoimmun
respons
level
ms
popul
report
downregul
csf
liguori
et
al
downregul
potenti
biomark
ms
furthermor
one
may
also
envisag
treatment
current
approv
diseas
modifi
therapi
would
affect
dysregul
endogen
thymosin
system
ms
thu
may
interest
investig
whether
endogen
andor
express
level
cell
sera
modifi
patient
undergo
treatment
diseasemodifi
therapi
particular
immunemodulatori
therapi
glatiram
acet
teriflunomid
could
impact
low
circul
level
andor
ms
patient
possibl
combin
synthet
b
celldirect
therapeut
specif
mab
ocrelizumab
ofatunumab
mab
includ
natalizumab
alemtuzumab
affect
b
lymphocyt
may
complement
abil
affect
b
cell
compart
profound
rapid
deplet
b
cell
aris
treatment
mab
follow
replet
lymphocyt
regulatori
phenotyp
howev
case
exampl
follow
deplet
hyperpopul
immatur
b
cell
may
respons
secondari
autoimmun
major
drawback
alemtuzumab
therapi
baker
et
al
combin
regimen
chemotherapeut
plu
adopt
treatment
mani
cancer
type
garaci
et
al
ms
combin
diseas
modifi
therapi
synthet
may
help
address
correctli
modul
repopul
b
cell
compart
toward
regulatori
antiinflammatori
phenotyp
furthermor
induct
mediat
modul
innat
adapt
immun
respons
wu
chen
exampl
increas
level
suppress
respons
reduc
lesion
treg
inhibit
signal
transduc
activ
transcript
lu
et
al
diminish
adhes
cell
endotheli
cell
wu
et
al
current
fdaapprov
diseas
modifi
therapi
ms
mainli
focu
immunomodul
lack
remyelin
treatment
review
demonstr
promot
remyelin
synaptogenesi
axon
growth
addit
effect
immunosuppress
futur
clinic
treatment
may
employ
monotherapi
combin
diseas
modifi
therapi
treat
ms
patient
thu
therapeut
approach
attempt
decreas
sever
diseas
immunosupress
order
reduc
damag
myelin
axon
well
promot
repair
damag
myelin
axon
therebi
enhanc
function
recoveri
ms
patient
believ
studi
need
address
interest
aspect
thymosin
biolog
effect
ms
patient
eae
model
mind
treat
ms
patient
alon
togeth
approv
drug
may
meet
requir
desir
butstillunknown
therapi
ms
act
immun
dysregul
cn
damag
work
part
support
grant
italian
ministri
health
ms
